COVID-19 Severity in Multiple SclerosisMaria Pia Sormani, Giovanna Borriello, Daiana Bezzini et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 74
Impact of natural menopause on multiple sclerosis: a multicentre studyDamiano Baroncini, Mauro Zaffaroni, Pietro Annovazzi et al.|Journal of Neurology Neurosurgery & Psychiatry|2019Cited by 70
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapiesDamiano Baroncini, Gıancarlo Comı, Angelo Ghezzi et al.|Multiple Sclerosis Journal|2016Cited by 68
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational studyDamiano Baroncini, Angelo Ghezzi, Mauro Zaffaroni et al.|Multiple Sclerosis Journal|2018Cited by 62
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Marta Simone et al.|JAMA Neurology|2021Cited by 62